Genetic mannose binding lectin deficiency is associated with airway microbiota diversity and reduced exacerbation frequency in COPD


Published in:
Thorax

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
Copyright the authors 2017.
This is an open access Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution and reproduction for non-commercial purposes, provided the author and source are cited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Download date:22. Oct. 2019
ORIGINAL ARTICLE

Genetic mannose binding lectin deficiency is associated with airway microbiota diversity and reduced exacerbation frequency in COPD


ABSTRACT

Background In cystic fibrosis and bronchiectasis, genetic mannose binding lectin (MBL) deficiency is associated with increased exacerbations and earlier mortality; associations in COPD are less clear. Preclinical data suggest MBL interferes with phagocytosis of Haemophilus influenzae, a key COPD pathogen. We investigated whether MBL deficiency impacted on clinical outcomes or microbiota composition in COPD.

Methods Patients with COPD (n=1796) underwent MBL genotyping; linkage to health records identified exacerbations, lung function decline and mortality. A nested subcohort of 141 patients, followed for up to 6 months, was studied to test if MBL deficiency was associated with altered sputum microbiota, through 16S rRNA PCR and sequencing, or airway inflammation during stable and exacerbated COPD.

Findings Patients with MBL deficiency with COPD were significantly less likely to have severe exacerbations (incidence rate ratio (IRR) 0.66, 95% CI 0.48 to 0.90, p=0.009), or to have moderate or severe exacerbations (IRR 0.77, 95% CI 0.60 to 0.99, p=0.047). MBL deficiency did not affect rate of FEV1 decline, or death. In the subcohort, patients with MBL deficiency had a more diverse lung microbiota (p=0.008), and were less likely to be colonised with Haemophilus spp. There were lower levels of airway inflammation in patients with MBL deficiency.

Interpretation Patients with MBL deficient genotype with COPD have a lower risk of exacerbations and a more diverse lung microbiota. This is the first study to identify a genetic association with the lung microbiota in COPD.

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is characterised by airway inflammation, with periods of symptom exacerbation, leading to irreversible airflow limitation, lung damage and mucus hypersecretion. COPD has multiple phenotypes and an unpredictable clinical course. Culture independent techniques have shown that lungs of healthy adults and patients with COPD harbour a diverse microbiota. It is likely that genetic influences affect disease outcomes and microbiota composition through modulation of host defence mechanisms. There are few studies of genetic modifiers of exacerbation risk in COPD, and no studies relating host genotype with lung microbiota.

Mannose binding lectin (MBL), an innate immune system component, activates the lectin complement pathway and opsonises organisms for phagocytosis; it accumulates in the lungs during inflammation. Individuals with specific single nucleotide polymorphisms (SNPs) of the MBL2 gene cannot form stable multimeric forms, leading to systemic deficiency of the MBL protein. Of the population, 10%–30% carry MBL deficient haplotypes but have no detectable phenotype when healthy. In populations with bronchiectasis or cystic fibrosis (CF), MBL deficiency is associated with more exacerbations (including severe exacerbations), faster decline in FEV1, and increased Pseudomonas aeruginosa colonisation. In COPD, associations between MBL deficiency and hospitalisations for acute exacerbations or more frequent exacerbations have been identified, whereas Eagan et al found no relationship between MBL plasma levels and COPD risk or disease severity. It could be assumed that MBL deficiency in COPD, CF or bronchiectasis would have similar effects but there are clear differences in the inflammatory profiles.
and microbiota of these diseases. MBL undergoes oxidation in the COPD airway; oxidised MBL suppresses macrophage phagocytosis of Haemophilus influenzae, a key COPD pathogen. Failed macrophage phagocytosis in COPD has been extensively described and is likely to contribute to exacerbation risk. Paradoxically, MBL deficiency could be beneficial in COPD, by removing a key inhibitor of macrophage function and bacterial clearance. This study was designed to test if MBL deficiency protects against exacerbations and is associated with a lower abundance of Haemophilus spp in the COPD airway.

METHODS
Tayside Allergy and Respiratory Disease Information System population based genetic study
In 2008, patients age >40 years; with an FEV1/FVC ratio <70% and a clinical diagnosis of COPD were invited to participate in a primary care based longitudinal cohort study and population registry called Tayside Allergy and Respiratory Disease Information System (TARDIS). Patients were reviewed annually for lung function performance, recording of symptoms and exacerbation history. The inclusion criteria were age >40 years, a postbronchodilator FEV1/FVC ratio <70% and a clinical diagnosis of COPD. Record linkage was used to obtain prescribing history, hospitalisations, morbidity and death, using the Scottish morbidity database, the Tayside community prescription database and the General Register Office for Scotland. Patients gave informed consent to participate. Saliva was collected for DNA extraction using Oragene kits (DNA Genotek). In the present analysis we excluded patients with a primary diagnosis of bronchiectasis, asthma or immunodeficiency.

SNP genotyping
TARDIS DNA samples were genotyped for four MBL2 SNPs (promoter region SNP rs7096206, and exon 1 SNPs rs1800450, rs1800451, rs5030737) which previous studies have used to define genetic MBL deficiency. Further details of SNP genotyping are shown in the online supplementary material. Patients were classified as deficient, intermediate or sufficient MBL genotype according to generally accepted definitions.

TARDIS outcomes
The primary outcome was to determine if MBL deficiency was associated with frequency of exacerbations. Exacerbations were recorded annually and validated against prescribing and hospital admission data. Local guidelines for COPD exacerbation management recommend 30–40 mg/day prednisolone with antibiotics prescribed in the presence of purulent sputum. Exacerbations were identified as an acute prescription for >20 mg/day of prednisolone (moderate exacerbations) and/or admission to hospital due to exacerbation of COPD (severe exacerbation). Prescribing data were used to distinguish between those exacerbations treated with corticosteroids alone or those also treated with antibiotics. Statistical models were constructed comparing MBL deficient and sufficient patients was performed using multiple linear regression. The annualised rate of FEV1 decline was determined from date of enrolment to death. Comparison of the average annual rate in decline of FEV1, between MBL deficient, intermediate and sufficient patients was performed using multiple linear regression. The annualised rate of FEV1 decline was determined from the difference between the FEV1 recorded at the final TARDIS visit and the baseline visit divided by follow-up time. Multivariable models were adjusted for gender, Deprivation Index, prescriptions for inhaled corticosteroids (ICS), bronchodilators and other medications (listed in table 1), smoking status and pack years, FEV1, post bronchodilator FEV1, comorbidities of cardiovascular disease, liver disease, renal disease, hypertension and diabetes. Data were obtained from record linkage and so no missing data were encountered for prescribing, morbidity and mortality data. Subgroups were predefined including examining exacerbations requiring corticosteroids versus those requiring antibiotics, and moderate versus severe exacerbations (defined as those requiring hospital admission). All models used

Microbiota subcohort study
Subsequently, a nested cohort of patients was recruited, based on MBL genotype, into a more detailed study to identify the impact of MBL deficiency on exacerbation risk. Patients with known MBL genotype, who were alive in 2013 and had given consent to be contacted again for research studies were approached by letter. Those that responded to the invitation were screened and included in the subcohort study.

Patients enrolled during a period of disease stability were followed up for between 3 months to 6 months. During this period, patients contacted the study team in the event of an exacerbation as defined in the online supplementary material. Blood and sputum samples for analysis of systemic and airway inflammation, and for examination of lung microbiota, were taken at the beginning and end of the study (when clinically stable) and at the beginning and 10 days after the start of exacerbations. Inclusion and exclusion criteria and study procedures are shown in the online supplementary material.

Systemic and airway inflammation
Sputum and serum biomarkers (interleukin (IL) 1β, IL-8 and tumour necrosis factor α (TNFα), extracellular newly identified receptor for advanced glycation end products binding protein (EN-RAGE), myeloperoxidase, C-reactive protein (CRP), CD40L, P-selectin) were measured by ELISA as described in the online supplementary material.

Sputum microbiota
DNA extracted from whole sputum underwent PCR and sequencing of the bacterial 16S rRNA gene on the Illumina MiSeq followed by bioinformatic analysis in the Quantitative Insights Into Microbial Ecology pipeline V1.9.0 as described in the online supplementary material.

Bacterial binding studies
The ability of MBL and the closely related molecules ficolins 2 and 3 to bind to clinically relevant respiratory pathogens were assessed in vitro as detailed in the online supplementary material.

Statistical analysis
Descriptive data are expressed as mean ±SD or count with percentage as appropriate. Sample size was empirical based on the number of available patients within the TARDIS cohort. Exacerbation frequency was evaluated using negative binomial models accounting for differing lengths of follow-up per patient. Survival was assessed by Cox proportional hazards regression from date of enrolment to death. Comparison of the average annual rate in decline of FEV1, between MBL deficient, intermediate and sufficient patients was performed using multiple linear regression. The annualised rate of FEV1 decline was determined from the difference between the FEV1 recorded at the final TARDIS visit and the baseline visit divided by follow-up time. Multivariable models were adjusted for gender, Deprivation Index, prescriptions for inhaled corticosteroids (ICS), bronchodilators and other medications (listed in table 1), smoking status and pack years, FEV1, post bronchodilator FEV1, comorbidities of cardiovascular disease, liver disease, renal disease, hypertension and diabetes. Data were obtained from record linkage and so no missing data were encountered for prescribing, morbidity and mortality data. Subgroups were predefined including examining exacerbations requiring corticosteroids versus those requiring antibiotics, and moderate versus severe exacerbations (defined as those requiring hospital admission). All models used

Chronic obstructive pulmonary disease
Table 1  Table showing the baseline characteristics of the Tayside Allergy and Respiratory Disease Information System (TARDIS) cohort analysis by mannose binding lectin (MBL) genotype. p Values were calculated by three-way comparisons (Kruskal-Wallis for non-parametrical data, analysis of variance for parametrical data and X² test for categorical data) across all groups

<table>
<thead>
<tr>
<th></th>
<th>MBL deficient genotype</th>
<th>MBL intermediate genotype</th>
<th>MBL sufficient genotype</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N (% of study cohort)</td>
<td>240 (13.4)</td>
<td>586 (32.6)</td>
<td>970 (54.0)</td>
<td>n/a</td>
</tr>
<tr>
<td>Average follow-up length in years (SD)</td>
<td>5.44 (±2.1)</td>
<td>5.34 (±2.0)</td>
<td>5.43 (±2.1)</td>
<td>0.9</td>
</tr>
<tr>
<td>Age at diagnosis, years (SD)</td>
<td>65.6 (±9.0)</td>
<td>64.23 (±9.6)</td>
<td>64.4 (±9.6)</td>
<td>0.1</td>
</tr>
<tr>
<td>Male gender (% of group)</td>
<td>131 (54.6)</td>
<td>308 (52.7)</td>
<td>506 (52.2)</td>
<td>0.8</td>
</tr>
<tr>
<td>Cigarette smoking by pack years (SD)</td>
<td>41.6 (±20.6)</td>
<td>41.0 (±20.3)</td>
<td>41.3 (±22.7)</td>
<td>0.7</td>
</tr>
<tr>
<td>Body mass index (SD)</td>
<td>27.0 (±5.6)</td>
<td>26.9 (±5.4)</td>
<td>27.2 (±5.6)</td>
<td>0.9</td>
</tr>
<tr>
<td>FEV₁ % predicted (SD)</td>
<td>79.6 (±20.8)</td>
<td>78.7 (±24.4)</td>
<td>78.0 (±22.1)</td>
<td>0.3</td>
</tr>
<tr>
<td>MRC Dyspnoea Score (SD)</td>
<td>2.44 (±1.0)</td>
<td>2.53 (±1.0)</td>
<td>2.48 (±1.0)</td>
<td>0.6</td>
</tr>
<tr>
<td>FEV₁/FVC (SD)</td>
<td>0.59 (±0.1)</td>
<td>0.58 (±0.1)</td>
<td>0.58 (±0.1)</td>
<td>0.3</td>
</tr>
</tbody>
</table>

Comorbidities

Cardiovascular disease (% of group) | 24 (10.0) | 53 (9.0) | 78 (8.0) | 0.6     |
Renal failure (% of group) | 5 (2.1) | 17 (2.9) | 19 (2.0) | 0.5     |
Cancer (% of group) | 12 (5.0) | 29 (4.9) | 39 (4.0) | 0.6     |
Hypertension (% of group) | 137 (57.1) | 322 (54.9) | 524 (54.0) | 0.7     |
Diabetes (% of group) | 48 (20.0) | 105 (17.9) | 194 (20.0) | 0.6     |

Therapies

Inhaled corticosteroids (% of group) | 123 (51.3) | 349 (59.6) | 570 (58.8) | 0.1     |
Long-acting muscarinic antagonist (% of group) | 67 (27.9) | 175 (29.9) | 257 (26.5) | 0.4     |
Statins (% of group) | 71 (29.6) | 178 (30.4) | 313 (32.3) | 0.6     |

RESULTS

TARDIS population-based genetic study

A flow chart detailing the numbers of samples in both cohorts is shown in figure 1, with 1796 patients included in this analysis; 53% were male, an average age of 64.3 years, a mean FEV₁ of 78% predicted, an FEV₁/FVC ratio of 0.58 and a smoking history of 41.26 pack years. Table 1 gives details of the cohort at baseline, split according to MBL genotype. There were no statistically significant differences in age, gender, FEV₁, body mass index, comorbidities and smoking status between the groups. Mean follow-up time was 5.4 years.

MBL deficiency is associated with reduced exacerbation frequency but not mortality in COPD

During follow-up the rate of exacerbations per patient per year was 2.52/year in the MBL sufficient haplotype group and 1.70/ year in patients with MBL deficient haplotypes. In the adjusted negative binomial model, MBL deficient haplotypes were associated with 23% fewer exacerbations (figure 2) compared with MBL sufficient individuals. A significant reduction in exacerbation frequency was observed when comparing MBL deficient versus sufficient genotypes, or when comparing patients with MBL deficiency with all other groups (incidence rate ratio (IRR) 0.74, 95% CI 0.56 to 0.98, p=0.04). The effect was greatest for severe exacerbations; MBL deficiency reduced the likelihood of hospitalisation by 34% (IRR 0.66, 95%CI 0.48 to 0.90, p=0.009), although there was no statistically significant difference on interaction testing (p=0.7), indicating no differential effect of MBL deficiency on severe and non-severe exacerbations. Sensitivity analysis showed the reduction in exacerbations was driven by a reduction in infective exacerbations requiring antibiotics (figure 2). The rates of FEV₁ decline were 38.4 mL/year in patients with MBL deficient haplotypes, 45.1 mL/year in those with intermediate haplotypes and 45.0 mL/year in those with sufficient haplotypes. In the adjusted linear regression model MBL deficiency was not associated with a more rapid decline in FEV₁ over time (estimate 0.27, SE 0.31, p=0.4). Similar results were obtained from the three-level and two-level models.

There were 589 deaths from any cause during follow-up (32.8% of the cohort). Three hundred and sixty deaths were classified as respiratory related, 133 were classified as cardiovascular and 96 were from other causes. The corresponding death rates for MBL deficient versus non-deficient groups were 31.3% versus 33.1% for all-cause mortality, 17.5% versus 20.5% for respiratory mortality and 6.3% versus 7.6% for cardiovascular deaths. In the adjusted analysis, MBL deficiency (deficient vs non-deficient) was not associated with respiratory (HR 0.83, 95%CI 0.56 to 1.35, p=0.4), cardiovascular (HR 0.81, 95%CI 0.44 to 1.48, p=0.5) or all-cause mortalities (HR 0.94, 95%CI 0.72 to 1.24, p=0.7) (figure 2). Similar results were obtained using the three-level model. Intermediate expressing haplotypes were not associated with increased exacerbation frequency compared with sufficient haplotypes (IRR 0.98, 95%CI 0.82 to 1.18, p=0.8).
Figure 2  Risk of exacerbations, cardiovascular hospitalisations and mortality according to mannose binding lectin (MBL)2 genotype. Two models were made comparing MBL sufficient, intermediate and deficient genotypes (three-level model) and comparing MBL deficient to non-deficient (intermediate and sufficient combined) genotypes (two-level model). A rate ratio >1 indicates a lower risk of exacerbation, hospitalisation or mortality with low expressing genotypes. Results are significant at p<0.05 where the 95% CI does not cross a ratio of 1.0.

Microbiota subcohort study
Based on the finding of less frequent and fewer infective exacerbations in patients with MBL deficiency, we recruited two subcohorts of patients with TARDIS COPD by MBL genotype to compare the microbiota and inflammatory profiles between these subcohorts (figure 1, n=141). Thirty-four patients were classified as MBL deficient and 107 as MBL non-deficient by genotypes. At baseline, patients with MBL deficient and non-deficient genotypes were well matched in terms of Medical Research Council (MRC) Dyspnoea Score, quality of life (St George’s Respiratory Questionnaire), symptoms (COPD assessment test), Global Obstructive Lung Disease (GOLD) 2011 class and per cent predicted FEV1 (table 2).

MBL deficiency is associated with an increased diversity in microbiota
Forty-two patients could not provide sputum samples during the study; comparisons between sputum producers and the whole cohort (online supplementary table E1) indicated there was no significant difference in baseline characteristics between sputum producers and non-producers. Two hundred and ten sputum samples were obtained; 184 sputum samples were of sufficient quality and quantity for successful bacterial DNA extraction and 16S rRNA gene sequencing. One hundred and twenty-six samples passed the subsequent data analysis quality control cut-offs; 89 were from patients when clinically stable, 16 were start of exacerbation and 21 were end of exacerbation samples.

Figure 3A shows one representative stable microbiota from each patient, alongside a comparison of the averaged microbiota profiles for the MBL deficient versus non-deficient populations (figure 3B). α Diversity (a measure of the evenness and richness of the microbiota of individual samples) was determined by Shannon-Wiener Diversity Index (S-WDI); patients with MBL deficiency had a more diverse lung microbiota than patients without MBL deficiency (p=0.008, figure 3D) and were less likely to be colonised with Haemophilus spp (figure 4B, p=0.043). Decreasing α diversity (lower S-WDI) was associated with more severe GOLD Score (figure 3E, p=0.045), with two clusters of S-WDI being driven by the percentage of operational taxonomic units (OTUs) identified as Haemophilus spp (figure 3F). The β diversity, a measurement of how different individual samples microbiota are from each other, of all stable samples is shown in the online supplementary figure E1.

Haemophilus spp dominance is associated with disease severity and increased airway inflammation
The dominant Haemophilus spp in 39.2% of the stable patients, identified by a BLASTn search (https://blast.ncbi.nlm.nih.gov/ Blast.cgi) of representative sequences of each Haemophilus OTU, was H. influenzae (figure 4A). A cut-off of 40% Haemophilus spp OTUs (based on figure 3F) was used to stratify patients as Haemophilus spp dominant and compared with markers of disease severity and exacerbation frequency (figure 4C,D). A more severe GOLD Score and more exacerbations per year were associated with having >40% Haemophilus spp OTUs (both p=0.03).

Lung inflammatory profiles, including IL-1β (previously shown to distinguish between infectious and non-infectious drivers of inflammation in COPD16), were compared between samples with less than or greater than 40% Haemophilus spp OTUs. Significantly higher levels of IL-1β (p<0.0001) and TNFα (p<0.0001) were observed in sputum samples from stable patients with >40% Haemophilus spp OTUs (figure 4E,F). Systemic markers of inflammation or sputum myeloperoxidase, EN-RAGE or IL-8 were not significantly different in patients categorised according to % Haemophilus spp OTUs.
Table 2  Baseline characteristics of the patients with mannose binding lectin (MBL) deficiency and patients without MBL deficiency in the microbiome subcohort study. GOLD class was calculated based on the 2011 guidelines. p Values were calculated through pairwise comparisons by T test for parametrical data and Mann-Whitney U test for non-parametrical data.

<table>
<thead>
<tr>
<th>Demographics and major comorbidities</th>
<th>MBL deficient genotypes</th>
<th>MBL non-deficient genotypes</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>34</td>
<td>107</td>
<td></td>
</tr>
<tr>
<td>Age, years (SD)</td>
<td>72.8 (±7.3)</td>
<td>70.8 (±8.2)</td>
<td>0.2</td>
</tr>
<tr>
<td>Age at diagnosis, years (SD)</td>
<td>59.5 (±9.1)</td>
<td>62.0 (±11.9)</td>
<td>0.8</td>
</tr>
<tr>
<td>Male gender (%)</td>
<td>22 (64.7)</td>
<td>67 (62.6)</td>
<td>0.8</td>
</tr>
<tr>
<td>Active smokers (%)</td>
<td>7 (20.6)</td>
<td>21 (19.6)</td>
<td>0.9</td>
</tr>
<tr>
<td>Cigarette smoking by pack (SD)</td>
<td>45.1 (±29.9)</td>
<td>41.7 (±28.9)</td>
<td>0.6</td>
</tr>
<tr>
<td>Body mass index (SD)</td>
<td>28.2 (±5.3)</td>
<td>28.1 (±5.6)</td>
<td>0.9</td>
</tr>
<tr>
<td>Myocardial infarction (%)</td>
<td>4 (12.1)</td>
<td>12 (11.2)</td>
<td>0.9</td>
</tr>
<tr>
<td>CABG (%)</td>
<td>3 (8.8)</td>
<td>12 (11.2)</td>
<td>0.7</td>
</tr>
<tr>
<td>Angina (%)</td>
<td>6 (18.2)</td>
<td>24 (22.4)</td>
<td>0.6</td>
</tr>
<tr>
<td>Stroke (%)</td>
<td>7 (20.6)</td>
<td>6 (5.6)</td>
<td>0.008</td>
</tr>
<tr>
<td>Diabetes (%)</td>
<td>5 (14.7)</td>
<td>22 (20.6)</td>
<td>0.4</td>
</tr>
<tr>
<td>COPD characteristics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV1, percent predicted (SD)</td>
<td>65.0 (±19.4)</td>
<td>72.1 (±20.7)</td>
<td>0.08</td>
</tr>
<tr>
<td>MRC Dyspnoea Score (SD)</td>
<td>3.0 (±1.5)</td>
<td>2.58 (±1.4)</td>
<td>0.1</td>
</tr>
<tr>
<td>Exacerbations per year (SD)</td>
<td>1.5 (±1.5)</td>
<td>1.9 (±1.9)</td>
<td>0.3</td>
</tr>
<tr>
<td>Blood eosinophils &gt;2% (%)</td>
<td>16 (47.1)</td>
<td>70 (65.4)</td>
<td>0.06</td>
</tr>
<tr>
<td>GOLD Score</td>
<td></td>
<td></td>
<td>0.6*</td>
</tr>
<tr>
<td>A (%)</td>
<td>2 (5.9)</td>
<td>15 (14.0)</td>
<td>–</td>
</tr>
<tr>
<td>B (%)</td>
<td>14 (41.2)</td>
<td>38 (35.5)</td>
<td>–</td>
</tr>
<tr>
<td>C (%)</td>
<td>2 (5.9)</td>
<td>4 (3.7)</td>
<td>–</td>
</tr>
<tr>
<td>D (%)</td>
<td>16 (47.1)</td>
<td>50 (46.7)</td>
<td>–</td>
</tr>
<tr>
<td>SGRQ (SD)</td>
<td>47.8 (±23.3)</td>
<td>39.7 (±22.6)</td>
<td>0.07</td>
</tr>
<tr>
<td>On LTOT (%)</td>
<td>0 (0)</td>
<td>5 (4.7)</td>
<td>0.2</td>
</tr>
<tr>
<td>Medications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICS/LABA (%)</td>
<td>22 (64.7)</td>
<td>62 (57.9)</td>
<td>0.5</td>
</tr>
<tr>
<td>LABA alone (%)</td>
<td>3 (8.8)</td>
<td>13 (12.1)</td>
<td>0.6</td>
</tr>
<tr>
<td>LAMA (%)</td>
<td>19 (55.9)</td>
<td>51 (47.7)</td>
<td>0.4</td>
</tr>
<tr>
<td>Mucolytic (%)</td>
<td>7 (20.6)</td>
<td>10 (9.3)</td>
<td>0.08</td>
</tr>
<tr>
<td>Aspirin (%)</td>
<td>10 (28.4)</td>
<td>27 (25.2)</td>
<td>0.6</td>
</tr>
<tr>
<td>β blocker (%)</td>
<td>5 (14.7)</td>
<td>13 (12.1)</td>
<td>0.7</td>
</tr>
<tr>
<td>Statin (%)</td>
<td>20 (58.6)</td>
<td>56 (52.3)</td>
<td>0.5</td>
</tr>
<tr>
<td>ACE inhibitor (%)</td>
<td>7 (20.6)</td>
<td>30 (28.0)</td>
<td>0.4</td>
</tr>
<tr>
<td>Clopidogrel (%)</td>
<td>3 (8.8)</td>
<td>7 (6.5)</td>
<td>0.7</td>
</tr>
</tbody>
</table>

*indicates X² test across all four GOLD groups.
CABG, coronary artery bypass graft; GOLD, Global Obstructive Lung Disease; ICS, inhaled corticosteroids; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; LTOT, long-term oxygen therapy; SGRQ, St George’s Respiratory Questionnaire.

M BL deficiency is associated with reduced airway inflammation
Taking one stable sample from each patient, MBL deficiency was associated with decreased sputum concentrations of EN-RAGE and IL-1β (p=0.046 and p=0.032, respectively, figure 5); there were no significant differences with other markers of inflammation (serum CRP, serum CD40L, serum P-selectin, sputum IL-8, sputum TNF-α or sputum myeloperoxidase). MBL deficiency in patients with COPD is associated with less airway inflammation.

M BL binds Haemophilus spp but not P. aeruginosa or Streptococcus pneumoniae
Since MBL deficiency was protective against Haemophilus dysbiosis but not other potential respiratory pathogens, and because MBL binding is required for its effect on phagocytosis, we hypothesised that MBL would bind H. influenzae. We investigated the ability of MBL to bind to respiratory pathogens in vitro. We observed that MBL bound to H. influenzae, along with Staphylococcus aureus, Burkholderia cenocepacia and Escherichia coli but did not bind to P. aeruginosa, or Streptococcus pneumoniae (figure 6).

DISCUSSION
This study demonstrates that MBL deficiency is associated with a significantly lower frequency of exacerbations in a large cohort of patients with COPD. In the microbiota subcohort, MBL deficiency was associated with a more diverse microbiota, and in particular, a reduction in Haemophilus spp OTUs. Loss of microbiota diversity with dominance of Haemophilus spp is associated with more severe disease, more frequent exacerbations and greater airway inflammation. Our finding that MBL deficiency is protective against Haemophilus spp infection is consistent with data showing that oxidised MBL disrupts MBL oligomer formation and inhibits phagocytic clearance of Haemophilus spp in COPD alveolar macrophages. Impaired phagocytosis of Haemophilus spp in COPD macrophages has been previously demonstrated; our data fit with the proposal that MBL has a role in inhibiting clearance of bacteria from the airway. MBL deficiency may be beneficial, by removing an inhibitory factor preventing bacterial phagocytosis. The 23% reduction in exacerbations we observed in the MBL deficient group is clinically important, and is equivalent to the reduction observed when ICS are added to long-acting β agonists in randomised controlled trials.

Our COPD data contrast to CF and bronchiectasis data, where poor outcomes are most strongly associated with P. aeruginosa infection. MBL deficiency increases the frequency and severity of P. aeruginosa infections in humans and mice, while studies show lower mortality in patients infected with H. influenzae compared with P. aeruginosa and other bacteria. In the largest bronchiectasis cohort study, colonisation with H. influenzae was associated with a lower frequency of exacerbations compared with P. aeruginosa or Veillonella spp colonisation. COPD, bronchiectasis and CF have differing microbiota and inflammatory profiles and very different clinical presentations. Therefore, it is plausible MBL deficiency may have different impacts in different diseases. Indeed it has been long speculated that the high MBL deficiency frequency in the population suggests a balanced effect whereby it is harmful under some circumstances but beneficial under others.

The effect in this study appeared to be relatively specific for H. influenzae. We found that MBL bound to H. influenzae in vitro, but not to other clinically relevant bacteria except S. aureus and B. cenocepacia which are pathogens more frequently isolated in CF than in COPD. The specificity for H. influenzae in COPD is therefore likely to reflect the requirement for oxidised MBL to...
bind in order to inhibit phagocytosis, combined with the high prevalence of *H. influenzae* in patients with COPD.

Previous studies on the impact of MBL deficiency in COPD are inconsistent; none have enrolled >300 patients without preselection for a subset of patients with COPD, that is, frequent exacerbators,23 or had sufficient follow-up time to evaluate exacerbation frequency, whereas we analysed the electronic medical record data from 1796 patients with COPD with an average follow-up of 5.4 years. In the present study, MBL deficiency status was not found to have an effect on decline in FEV₁, mortality or hospital admissions for cardiovascular events. The study was not specifically powered for these exploratory end points, however, larger studies or longer follow-up will be needed to thoroughly investigate these outcomes.

Compared with the human gastrointestinal tract microbiota, relatively little is known about the lung microbiota both in health and various lung disease states. The majority of COPD lung microbiota studies have low patient numbers with limited longitudinal sampling, confounded by different sample collection techniques, in populations with varying disease severity or bacterial colonisation status.2 24–26 In comparison, we were able to obtain sputum from a larger cohort of patients with COPD. While there are concerns that the oral microbiota may contaminate sputum,27 induced sputum was chosen due to its less invasive nature (compared with bronchoscopy) and the likelihood of obtaining sufficient sample for sequencing. Our results, showing a stable microbiota dominated by *Haemophilus*, *Veillonella*, *Prevotella* and *Streptococcus* spp, are similar to those obtained by other sample collection methods,2 24–26 and from healthy smokers and non-smokers.27 Additionally our data indicating a reduction in α diversity in more severe COPD and with a non-deficient genotype correlate with other studies which have compared the lung microbiota of different COPD stages with healthy smokers and non-smokers.2 We observed relatively few *Pseudomonas* genera OTUs.2 24–26 Our study was community based, examining a patient population with less severe COPD than other studies, and may be more representative of the wider patient population with COPD since *Pseudomonas* spp are known colonisers in more severe COPD and...
**Figure 4**  
(A) Graph showing only the *Haemophilus* spp operational taxonomic units (OTUs) from each sample further identified to species level indicating the dominant *Haemophilus* spp was *Haemophilus influenzae*; all samples were from stable patients and each patient was only represented once. (B) Mean percentage of OTUs identified as *Haemophilus* spp in patients with mannose binding lectin (MBL) deficiency and patients without MBL deficiency. (C) One stable sample per patient classified according to GOLD 2011 Score, colour coded according to whether the sample had >40% *Haemophilus* spp OTUs. (D) The percentage of OTUs identified as *Haemophilus* spp compared with the number of exacerbations per year. (E,F) Sputum IL-1β and TNFα concentrations from stable patients with COPD (one sample per patient) stratified according to percentage of *Haemophilus* spp OTUs in sample. (G) Example of an exacerbation dominated by *Haemophilus* spp compared with a non-*Haemophilus* spp dominated exacerbation. Statistical analysis of microbiota data was carried out using the non-parametrical Spearman correlation and Mann-Whitney test, where appropriate; graphs show mean with SE.
Chronic obstructive pulmonary disease

Figure 5  (A) Sputum EN-RAGE (S100A12) levels and (B) IL-1β levels from stable patients with COPD grouped according to mannose binding lectin (MBL) genotype. Statistical analysis was carried out using the non-parametrical Mann-Whitney test.

bronchiectasis. We observed a clear correlation between clinical disease severity and microbiota diversity using S-WDI, similar to the reduced lung microbiota diversity shown to be associated with more severe COPD in other studies.

This study is the first to have sufficient statistical power to demonstrate correlations between microbiota diversity and disease severity or inflammatory profiles, both during clinical stability and at exacerbation. In addition, this is the first study to show a significant genetic modifier of the lung microbiota, although whether this modification is direct (through modulation of host immunity) or indirect (through protecting against antibiotic use for example), is unclear. This finding needs to be validated, but it is logical to expect that host genetics can influence the composition of the microbiota.

Proinflammatory IL-1β, one of the most useful discriminators of bacterial infection in COPD, promotes neutrophil recruitment. Neutrophilic inflammation contributes to COPD progression, and is poorly responsive to ICS. We identified higher levels of IL-1β and the RAGE ligand S100A12 (EN-RAGE) in sputum from patients without MBL deficiency. Although elevated IL-1β may be a reflection of the lower bacterial diversity in individuals without MBL deficiency, it has previously been shown that exposure to MBL can promote increased release of IL-1β in response to Gram-negative pathogens like Neisseria meningitides or by lipopolysaccharide, suggesting that MBL can be directly responsible for increased inflammation, independent of its effect as an opsonin.

Figure 6  Binding of lectin pathway components to respiratory pathogens. Binding is expressed as a percentage of the positive control (acetylated bovine serum albumin for ficolin-2/ficolin-3 and mannan for mannose binding lectin (MBL)). Binding assays represent the mean with SE of three independent experiments performed in duplicate.

Limitations of the Go-TARDIS study include the use of primary care diagnosis, hospitalisation records and prescription data to identify exacerbations, however, these are widely used epidemiological methods. The patient population consisted of primarily early COPD with preserved lung function, and hence the generalisability of these data to later stage COPD would need to be confirmed in other studies. The sample size in the microbiota subcohort study was relatively small, reflecting the fact that MBL deficiency affects only 10% of the population; larger, multinational studies would be valuable. Nevertheless, this represents the largest study of the microbiota in COPD to date and the largest study of the impact of genetic MBL deficiency in COPD.

In conclusion, we have shown, using a large primary care based genetic study and a nested microbiota subcohort study, MBL deficiency in COPD is protective against the risk of exacerbations and is associated with a more diverse lung microbiota. MBL genotype is a modifier of disease phenotype and exacerbation risk in COPD.

Acknowledgements The authors thank the Health Informatics Centre, University of Dundee for managing and supplying anonymized data and NHS Tayside, the original data source. The authors also thank Mike Lonergan and Peter T Donnan for additional statistical support.

Contributors All authors participated in study design, data analysis and interpretation of the data. All authors were involved in writing and revising the article prior to submission.

Funding Chief Scientist Office, Scotland (ETM/262). JDC is supported by the GSK/British Lung Foundation Chair of Respiratory Research and a fellowship from the Wellcome Trust (099084/Z/12/Z). GoSHARE was supported by the Wellcome Trust (099177/Z/12/Z).

Competing interests SEM is now an employee of the Wellcome Trust. All other authors have no competing interest to declare.

Patient consent Obtained.

Ethics approval East of Scotland Research Ethics Committee.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Data are available and can be accessed through the Health Informatics Centre at the University of Dundee.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES


Chronic obstructive pulmonary disease


22 Eisen DP, O’Shoff M. If there is an evolutionary selection pressure for the high frequency of MBL2 polymorphisms, what is it? Clin Exp Immunol 2014;176:165–71.


Genetic mannose binding lectin deficiency is associated with airway microbiota diversity and reduced exacerbation frequency in COPD

Alison J Dicker, Megan L Crichton, Andrew J Cassidy, Gill Brady, Adrian Hapca, Roger Tavendale, Gisli G Einarsson, Elizabeth Furrie, J Stuart Elborn, Stuart Schembri, Sara E Marshall, Colin N A Palmer and James D Chalmers

Thorax published online November 3, 2017

Updated information and services can be found at:
http://thorax.bmj.com/content/early/2017/11/03/thoraxjnl-2016-209931

These include:

References
This article cites 31 articles, 4 of which you can access for free at:
http://thorax.bmj.com/content/early/2017/11/03/thoraxjnl-2016-209931#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Open access (270)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/